Skip to main content
. 2019 Oct 10;10(6):2153–2167. doi: 10.1007/s13300-019-00701-3

Table 4.

First-year and following year treatment costs of each alternative (CDM inputs of treatment cost group setting; GBP)

1st year Subsequent years
Empagliflozin + SoC 816.65 833.97
Sitagliptin + SoC 599.84 668.35
Saxagliptin + SoC 710.97 721.56
Basal bolus 1718.91 1718.91

SoC standard of care